Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 352

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 352
---
.20.          | Interest rate swaps                                                                                | Fair value           |                           2 | Revenue-basedapproach            | Present value offuture cash flows                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | MidMarketSpot | < 1 year:Mid Money Market  andLIFFE interest rate futures> 1 year:Mid Zero Coupon |
| D.20.          | Cross-currency swaps                                                                               | Fair value           |                           2 |                                  | Present value offuture cash flows                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | MidMarketSpot | < 1  year:Mid Money Market andLIFFE interest rate futures> 1 year:Mid Zero Coupon |
| D.18.          | Liabilities related to business combinationsand to non-controlling interests (CVRs)                | Fair value           |                           1 | Market value                     | Quoted marketprice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |               |                                                                                   |
| D.18.          | Liabilities related to business combinationsand to non-controlling interests (other thanCVRs)      | Fair value           |                           3 | Revenue-basedapproach            | Under IAS 32, contingent consideration payable in a businesscombination is a financial liability. The fair value of suchliabilities is determined by adjusting the contingentconsideration at the end of the reporting period using themethod described in Note B.8.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                |               |                                                                                   |

(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes

changes in fair value attributable to the hedged risk(s).

| SANOFIFORM 20-F2024 | F-23 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

B.8.6. Derecognition of financial instruments Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset. A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished. B.8.7. Risks relating to financial instruments Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors